Logo image of TEVA

TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis

NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD

17.56  -0.5 (-2.77%)

After market: 17.5 -0.06 (-0.34%)

Fundamental Rating

4

Taking everything into account, TEVA scores 4 out of 10 in our fundamental rating. TEVA was compared to 193 industry peers in the Pharmaceuticals industry. While TEVA is still in line with the averages on profitability rating, there are concerns on its financial health. TEVA is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

TEVA had positive earnings in the past year.
TEVA had a positive operating cash flow in the past year.
TEVA had negative earnings in 4 of the past 5 years.
In the past 5 years TEVA always reported a positive cash flow from operatings.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B -15B

1.2 Ratios

Looking at the Return On Assets, with a value of -0.39%, TEVA is in the better half of the industry, outperforming 79.79% of the companies in the same industry.
With an excellent Return On Equity value of -2.31%, TEVA belongs to the best of the industry, outperforming 80.31% of the companies in the same industry.
TEVA has a Return On Invested Capital of 10.49%. This is amongst the best in the industry. TEVA outperforms 86.53% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TEVA is significantly below the industry average of 15.57%.
The last Return On Invested Capital (10.49%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.39%
ROE -2.31%
ROIC 10.49%
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

The Operating Margin of TEVA (22.59%) is better than 89.12% of its industry peers.
In the last couple of years the Operating Margin of TEVA has grown nicely.
TEVA has a Gross Margin of 50.88%. This is in the better half of the industry: TEVA outperforms 64.25% of its industry peers.
In the last couple of years the Gross Margin of TEVA has grown nicely.
Industry RankSector Rank
OM 22.59%
PM (TTM) N/A
GM 50.88%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
TEVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TEVA has more shares outstanding
TEVA has a better debt/assets ratio than last year.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

TEVA has an Altman-Z score of 0.61. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.61, TEVA perfoms like the industry average, outperforming 56.48% of the companies in the same industry.
TEVA has a debt to FCF ratio of 19.36. This is a negative value and a sign of low solvency as TEVA would need 19.36 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 19.36, TEVA is doing good in the industry, outperforming 75.65% of the companies in the same industry.
TEVA has a Debt/Equity ratio of 2.46. This is a high value indicating a heavy dependency on external financing.
TEVA has a worse Debt to Equity ratio (2.46) than 78.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.46
Debt/FCF 19.36
Altman-Z 0.61
ROIC/WACC1.43
WACC7.34%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.06 indicates that TEVA should not have too much problems paying its short term obligations.
TEVA has a worse Current ratio (1.06) than 80.31% of its industry peers.
TEVA has a Quick Ratio of 1.06. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.77, TEVA is not doing good in the industry: 82.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.77
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TEVA have decreased by -4.09% in the last year.
The Earnings Per Share has been decreasing by -1.18% on average over the past years.
The Revenue has been growing slightly by 2.07% in the past year.
The Revenue has been decreasing by -0.41% on average over the past years.
EPS 1Y (TTM)-4.09%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.2%
Revenue 1Y (TTM)2.07%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%0.29%

3.2 Future

Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 6.08% on average per year.
TEVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.20% yearly.
EPS Next Y4.61%
EPS Next 2Y3.56%
EPS Next 3Y6.08%
EPS Next 5YN/A
Revenue Next Year3.86%
Revenue Next 2Y1.99%
Revenue Next 3Y2.2%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 6.73, which indicates a rather cheap valuation of TEVA.
Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 95.34% of the companies are valued more expensively.
TEVA's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.85.
TEVA is valuated cheaply with a Price/Forward Earnings ratio of 6.50.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 92.75% of the companies listed in the same industry.
TEVA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.98.
Industry RankSector Rank
PE 6.73
Fwd PE 6.5
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TEVA is valued cheaper than 90.67% of the companies in the same industry.
TEVA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TEVA is cheaper than 82.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.63
EV/EBITDA 7.48
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.46
PEG (5Y)N/A
EPS Next 2Y3.56%
EPS Next 3Y6.08%

More info and screens

0

5. Dividend

5.1 Amount

TEVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (8/19/2025, 7:21:50 PM)

After market: 17.5 -0.06 (-0.34%)

17.56

-0.5 (-2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-30 2025-07-30/dmh
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners6.95%
Inst Owner Change1.01%
Ins Owners0.43%
Ins Owner Change5.15%
Market Cap20.14B
Analysts42.22
Price Target0.05 (-99.72%)
Short Float %4.44%
Short Ratio4.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.24%
Min EPS beat(2)4.65%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.88%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.79%
EPS beat(12)7
Avg EPS beat(12)-0.36%
EPS beat(16)9
Avg EPS beat(16)-0.6%
Revenue beat(2)0
Avg Revenue beat(2)-4.72%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)-4.68%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)2.63%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)6
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-1.7%
PT rev (1m)3.14%
PT rev (3m)3.34%
EPS NQ rev (1m)-6.75%
EPS NQ rev (3m)-5.83%
EPS NY rev (1m)1.99%
EPS NY rev (3m)2%
Revenue NQ rev (1m)-3.17%
Revenue NQ rev (3m)-2.83%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-0.48%
Valuation
Industry RankSector Rank
PE 6.73
Fwd PE 6.5
P/S 1.21
P/FCF 22.63
P/OCF 14.49
P/B 2.95
P/tB N/A
EV/EBITDA 7.48
EPS(TTM)2.61
EY14.86%
EPS(NY)2.7
Fwd EY15.39%
FCF(TTM)0.78
FCFY4.42%
OCF(TTM)1.21
OCFY6.9%
SpS14.5
BVpS5.95
TBVpS-11.56
PEG (NY)1.46
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.39%
ROE -2.31%
ROCE 13.29%
ROIC 10.49%
ROICexc 11.36%
ROICexgc 49.13%
OM 22.59%
PM (TTM) N/A
GM 50.88%
FCFM 5.35%
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexcg growth 3Y25.78%
ROICexcg growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score6
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 2.46
Debt/FCF 19.36
Debt/EBITDA 3.51
Cap/Depr 48.92%
Cap/Sales 3.01%
Interest Coverage 250
Cash Conversion 29.09%
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.77
Altman-Z 0.61
F-Score6
WACC7.34%
ROIC/WACC1.43
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.09%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.2%
EPS Next Y4.61%
EPS Next 2Y3.56%
EPS Next 3Y6.08%
EPS Next 5YN/A
Revenue 1Y (TTM)2.07%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%0.29%
Revenue Next Year3.86%
Revenue Next 2Y1.99%
Revenue Next 3Y2.2%
Revenue Next 5YN/A
EBIT growth 1Y1.19%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year16.85%
EBIT Next 3Y9.19%
EBIT Next 5YN/A
FCF growth 1Y-24.19%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-18.04%
OCF growth 3Y16.04%
OCF growth 5Y10.76%